Efficacy and Safety of Cariprazine in Acute Exacerbation of Schizophrenia: Results from an International, Phase III Clinical Trial

Journal of Clinical Psychopharmacology

Volumn 35, Issue 4, 2015, Pages 367-373

  Kane, John M ^a   Zukin, Stephen ^b   Wang, Yao ^b   Lu, Kaifeng ^b   Ruth, Adam ^c   Nagy, Krisztián ^d   Laszlovszky, István ^d   Durgam, Suresh ^b  

^a ZUCKER HILLSIDE HOSPITAL   (United States)

^b FOREST RESEARCH INSTITUTE   (United States)

^c Prescott Medical Communications Group   (United States)

^d GEDEON RICHTER LTD   (Hungary)

Author keywords

antipsychotic; cariprazine; dopamine; dopamine D3; receptors; schizophrenia

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; CARIPRAZINE; PLACEBO; PROLACTIN; PROPRANOLOL; NEUROLEPTIC AGENT; PIPERAZINE DERIVATIVE;

ADULT; AKATHISIA; ARTICLE; CLINICAL GLOBAL IMPRESSION SCALE; CONSTIPATION; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; DYSPEPSIA; ELECTROCARDIOGRAM; ELEVATED BLOOD PRESSURE; EXTRAPYRAMIDAL SYNDROME; FEMALE; HOSPITALIZATION; HUMAN; HYPERTRIGLYCERIDEMIA; INSOMNIA; MAJOR CLINICAL STUDY; MALE; NAUSEA; OPHTHALMOLOGY; ORTHOSTATIC HYPOTENSION; PHASE 3 CLINICAL TRIAL; POSITIVE AND NEGATIVE SYNDROME SCALE; PRIORITY JOURNAL; PROLACTIN BLOOD LEVEL; PSYCHOSIS; RANDOMIZED CONTROLLED TRIAL; RESTLESSNESS; SCHIZOPHRENIA; SIDE EFFECT; TOXIC HEPATITIS; TREATMENT DURATION; TREMOR; VOMITING; ACUTE DISEASE; CHEMICALLY INDUCED; CLINICAL TRIAL; HYPONATREMIA; INTERNATIONAL COOPERATION; MIDDLE AGED; MULTICENTER STUDY; TREATMENT OUTCOME;

ACUTE DISEASE; ADULT; ANTIPSYCHOTIC AGENTS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; HYPONATREMIA; INTERNATIONALITY; MALE; MIDDLE AGED; PIPERAZINES; PSYCHOSES, SUBSTANCE-INDUCED; SCHIZOPHRENIA; TREATMENT OUTCOME;

EID: 84936931469     PISSN: 02710749     EISSN: 1533712X     Source Type: Journal    
DOI: 10.1097/JCP.0000000000000346     Document Type: Article

References (51)

1. Kapur S, Mamo D. Half a century of antipsychotics and still a central role for dopamine D2 receptors. Prog Neuropsychopharmacol Biol Psychiatry. 2003;27:1081-1090.
2. Addington J, Addington D. Neurocognitive and social functioning in schizophrenia: a 2.5 year follow-up study. Schizophr Res. 2000;44:47-56.
3. Fitzgerald PB, Williams CL, Corteling N, et al. Subject and observer-rated quality of life in schizophrenia. Acta Psychiatr Scand. 2001;103:387-392.
4. Ho BC, Nopoulos P, Flaum M, et al. Two-year outcome in first-episode schizophrenia: predictive value of symptoms for quality of life. Am J Psychiatry. 1998;155:1196-1201.
5. Matsui M, Sumiyoshi T, Arai H, et al. Cognitive functioning related to quality of life in schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry. 2008;32:280-287.
6. Norman RM, Malla AK, McLean T, et al. The relationship of symptoms and level of functioning in schizophrenia to general wellbeing and the Quality of Life Scale. Acta Psychiatr Scand. 2000;102:303-309.
7. Savilla K, Kettler L, Galletly C. Relationships between cognitive deficits, symptoms and quality of life in schizophrenia. Aust N Z J Psychiatry. 2008; 42:496-504.
8. Cho DI, Zheng M, Kim KM. Current perspectives on the selective regulation of dopamine D(2) and D(3) receptors. Arch Pharm Res. 2010; 33:1521-1538.
9. Gross G, Drescher K. The role of dopamine D(3) receptors in antipsychotic activity and cognitive functions. Handb Exp Pharmacol. 2012:167-210.
10. Laszy J, Laszlovszky I, Gyertyán I. Dopamine D3 receptor antagonists improve the learning performance in memory-impaired rats. Psychopharmacology (Berl). 2005;179:567-575.
11. Millan MJ, Buccafusco JJ, Loiseau F, et al. The dopamine D3 receptor antagonist, S33138, counters cognitive impairment in a range of rodent and primate procedures. Int J Neuropsychopharmacol. 2010;13:1035-1051.
12. Sokoloff P, Giros B, Martres MP, et al. Molecular cloning and characterization of a novel dopamine receptor (D3) as a target for neuroleptics. Nature. 1990;347:146-151.
13. Schwartz JC, Diaz J, Pilon C, et al. Possible implications of the dopamineD (3) receptor in schizophrenia and in antipsychotic drug actions. Brain Res Brain Res Rev. 2000;31:277-287.
14. Gyertyán I, Sághy K, Laszy J, et al. Subnanomolar dopamine D3 receptor antagonism coupled to moderate D2 affinity results in favourable antipsychotic-like activity in rodentmodels: II. behavioural characterisation of RG-15. Naunyn Schmiedebergs Arch Pharmacol. 2008;378:529-539.
15. Kiss B, Horváth A, Némethy Z, et al. Cariprazine (RGH-188), a dopamine D(3) receptor-preferring, D(3)/D(2) dopamine receptor antagonist-partial agonist antipsychotic candidate: in vitro and neurochemical profile. J Pharmacol Exp Ther. 2010;333:328-340.
16. Kiss B, Horti F, Bobok A. Cariprazine, a D3/D2 dopamine receptor partial agonist antipsychotic, displays greater D3 receptor occupancy in vivo compared with other antipsychotics. Schizophr Res. 2012;136(suppl 1): S190.
17. Slifstein M, Abi-Dargham A, D'Souza DC, et al. Cariprazine demonstrates high dopamine D3 and D2 receptor occupancy in patients with schizophrenia: a clinical PET study with [11C]-(+)-PHNO. Neuropsychopharmacology. 2013;38:S520.
18. Gyertyán I,Kiss B, Sághy K, et al. Cariprazine (RGH-188), a potentD3/D2 dopamine receptor partial agonist, binds to dopamine D3 receptors in vivo and shows antipsychotic-like and procognitive effects in rodents. Neurochem Int. 2011;59:925-935.
19. Duman RS, Duric V, Banasr M, et al. Cariprazine exhibits dopamine D3 receptor-dependent antidepressant-like activity in the chronic unpredictable stress model of anhedonia. Neuropsychopharmacology. 2012;38:S84.
20. Zimnisky R, Chang G, Gyertyán I, et al. Cariprazine, a dopamine D(3)-receptor-preferring partial agonist, blocks phencyclidine-induced impairments of working memory, attention set-shifting, and recognition memory in the mouse. Psychopharmacology (Berl). 2013;226:91-100.
21. DurgamS, Starace A, LiD, et al. An evaluation of the safety and efficacy of cariprazine in patients with acute exacerbation of schizophrenia: a phase II, randomized clinical trial. Schizophr Res. 2014;152:450-457.
22. Lieberman JA, Cutler AJ,Wan S, et al. Cariprazine in acute exacerbation of schizophrenia: a fixed-dose, randomised, double-blind, placebo-and active-controlled trial. Eur Neuropsychopharmacol. 2013;23(suppl 2): S477-S478.
23. Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull. 1987;13:261-276.
24. Kay SR, Opler LA, Spitzer RL, et al. SCID-PANSS: two-tier diagnostic system for psychotic disorders. Compr Psychiatry. 1991;32:355-361.
25. Guy W. The Clinician Global Severity and Impression Scales. ECDEU Assessment Manual for Psychopharmacology. Rockville, MD: National Institute ofMental Health; 1976:218-222. DHEWPublication No. 76-338.
26. Posner K, Brown GK, Stanley B, et al. The Columbia-Suicide Severity Rating Scale: initial validity and internal consistency findings from three multisite studies with adolescents and adults. Am J Psychiatry. 2011;168: 1266-1277.
27. Axelrod BN, Goldman RS, Alphs LD. Validation of the 16-item Negative Symptom Assessment. J Psychiatr Res. 1993;27:253-258.
28. Martin CR, Allan R. Factor structure of the Schizophrenia Quality of Life Scale Revision 4 (SQLS-R4). Psychol Health Med. 2007;12:126-134.
29. Simpson PM, Surmon DJ, Wesnes KA, et al. The cognitive drug research computerized assessment system for demented patients: a validation study. Int J Geriatr Psychiatry. 1991;6:95-102.
30. D'Elia LF. Color Trails Test: Professional Manual. Lutz, FL: Psychological Assessment Resources; 1996.
31. Guy W. The Abnormal Movement Scale. ECDEU Assessment Manual for Psychopharmacology. Rockville,MD: National Institute ofMental Health; 1976:218-222. DHEW Publication No. 76-338.
32. Barnes TR. A rating scale for drug-induced akathisia. Br J Psychiatry. 1989;154:672-676.
33. Simpson GM, Angus JW. A rating scale for extrapyramidal side effects. Acta Psychiatr Scand Suppl. 1970;212:11-19.
34. Chen X, Luo X, Capizzi T. The application of enhanced parallel gatekeeping strategies. Stat Med. 2005;24:1385-1397.
35. Kenward MG, Molenberghs G, Thijs H. Pattern-mixture models with proper time dependence. Biometrika. 2003;90:53-71.
36. Mehta CR, Patel NR, Tsiatis AA. Exact significance testing to establish treatment equivalence with ordered categorical data. Biometrics. 1984;40: 819-825.
37. Johnson WD, May WL. Combining 2 - 2 tables that contain structural zeros. Stat Med. 1995;14:1901-1911.
38. Leucht S, Kane JM, Kissling W, et al. What does the PANSS mean? Schizophr Res. 2005;79:231-238.
39. FDA. Guidance for Industry. Drug-Induced Liver Injury: Premarketing Clinical Evaluation. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM174090. pdf. 2009; Accessed February 2013.
40. Blanchard JJ, Kring AM, Horan WP, et al. Toward the next generation of negative symptom assessments: the collaboration to advance negative symptom assessment in schizophrenia. Schizophr Bull. 2011;37:291-299.
41. Papp M, Gruca P, Lason-Tyburkiewicz M, et al. Attenuation of anhedonia by cariprazine in the chronic mild stress model of depression. Behav Pharmacol. 2014;25:567-574.
42. Durgam S, Lipschitz A, Guo H, et al. Cariprazine monotherapy in the treatment of bipolar depression: a double-blind, placebo-controlled study. Poster at: 29th CINP World College of Neuropsychopharmacology; June 22-26, 2014. Vancouver, B.C.
43. Durgam S, Mergel V, Earley W, et al. Cariprazine as adjunctive therapy in major depressive disorder: a double-blind, placebo-controlled study. Poster at: 29th CINP World College of Neuropsychopharmacology; June 22-26, 2014; Vancouver, B.C.
44. Solanki RK, Singh P, Midha A, et al. Schizophrenia: impact on quality of life. Indian J Psychiatry. 2008;50:181-186.
45. Huppert JD, Weiss KA, Lim R, et al. Quality of life in schizophrenia: contributions of anxiety and depression. Schizophr Res. 2001;51:171-180.
46. Reine G, Lancon C, Di Tucci S, et al. Depression and subjective quality of life in chronic phase schizophrenic patients. Acta Psychiatr Scand. 2003; 108:297-303.
47. Awad AG, Voruganti LN. Measuring quality of life in patients with schizophrenia: an update. Pharmacoeconomics. 2012;30:183-195.
48. Nuss P, Tessier C. Antipsychotic medication, functional outcome and quality of life in schizophrenia: focus on amisulpride. Curr Med Res Opin. 2010;26:787-801.
49. Weber NS, CowanDN,MillikanAM, et al. Psychiatric and general medical conditions comorbid with schizophrenia in the National Hospital Discharge Survey. Psychiatr Serv. 2009;60:1059-1067.
50. Newcomer JW, Haupt DW. The metabolic effects of antipsychotic medications. Can J Psychiatry. 2006;51:480-491.
51. DurgamS, Starace A, LiD, et al. The efficacy and tolerability of cariprazine in acute mania associated with bipolar I disorder: a phase II trial. Bipolar Disord. 2015;17:63-75.